Project Grant R01AR083948
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $354,200 to Virginia Polytechnic Institute & State University (Virginia Tech) to investigate the role of endothelial-derived reactive oxygen species (ROS) in regulating skeletal muscle metabolic responses to exercise. The research aims to elucidate the signaling mechanisms...
- This $144,500 federal Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to investigate the mechanisms by which exercise modulates vascular lipid metabolism and signaling pathways to maintain cardiovascular health. The project aims to develop in vitro approaches to recreate the physiological effects of exercise on endothelial cells, identify molecules that regulate lipid...
- This federal Project Grant award of $766,920.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research aimed at understanding the mechanisms linking skeletal muscle metabolism and vascular health in obesity. The primary research objectives are to investigate: 1) the role of the enzyme CYP1B1 in mediating skeletal muscle dysfunction and vascular injury in obesity, and 2) the impact of resolving myosteatosis...
- This $658,940 federal Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846) aims to investigate the mechanisms by which aerobic exercise impacts bone remodeling and resorption. The 5-year project, awarded on September 19, 2025 and running through August 31, 2030, will be conducted by the Regents of the University of Michigan. The research seeks to understand the processes by which aerobic activities like running and cycling...
- This $198,263 federal Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to advance the understanding of the role of the protein MG53 in regulating muscle mass during disuse-induced atrophy. The central hypothesis is that elevated levels of MG53 can reduce damaged mitochondria, lower reactive oxygen species accumulation, and thereby prevent...
- This $1,622,775 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the critical role of mitochondrial oxidative metabolism in determining muscle stem cell fate and function. The Van Andel Research Institute, a non-profit biomedical research organization in Grand Rapids, Michigan, will conduct this research over a 3-year period...
- This Project Grant award of $522,714 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the role of stretch activation in mammalian skeletal muscle endurance. The research will focus on measuring the characteristics and mechanisms of stretch activation in mouse slow-twitch and fast-twitch muscle fibers, including determining the specific myosin...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research Federal Grant Program (CFDA 93.846), provides $1,528,344.00 in funding to The Trustees of Columbia University in the City of New York to conduct research on the intricate mechanisms of excitation-contraction coupling in skeletal muscle weakness associated with heart failure. The research aims to identify oxidized cysteine...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 Arthritis, Musculoskeletal and Skin Diseases Research) provides $434,793 to the University of Arkansas to conduct research aimed at developing regenerative and rehabilitation strategies to reduce inflammation and improve muscle recovery following volumetric muscle loss (VML) injuries. The key objectives are to: 1) Determine the efficacy of endurance exercise in attenuating...
- The federal Project Grant award of $554,797 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to define the rate of myonuclear turnover in adult skeletal muscles, identify the mechanisms by which myonuclei are degraded, and unravel the targeting complexes and cellular pathways involved in this process. The central hypothesis is that accumulation of...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is providing $671,437 to Virginia Polytechnic Institute & State University (Virginia Tech) to investigate the role of endothelial reactive oxygen species (ROS) in exercise metabolism. The research aims to better understand how skeletal muscle cells, vascular endothelial cells, and other cell types coordinate their signaling in response to exercise stress, with a focus on the ROS-producing enzyme NADPH oxidase 4 (NOX4). The goal is to elucidate how endothelial signaling dependent on NOX4 contributes to the metabolic adaptation of skeletal muscle to exercise, with the potential to inform strategies for improving health and preventing disease. The project will be carried out over a period of approximately 5 years, from the award date of August 18, 2025 to the ultimate completion date of July 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $671.4k | 8/18/25 |